ANGIOPREDICT

Predictive Genomic Biomarkers Methods for Combination Bevacizumab (Avastin) Therapy in Metastatic Colorectal Cancer

 Coordinatore ROYAL COLLEGE OF SURGEONS IN IRELAND 

 Organization address address: Saint Stephen's Green 123
city: DUBLIN
postcode: 2

contact info
Titolo: Dr.
Nome: Annette
Cognome: Byrne
Email: send email
Telefono: 35314028673
Fax: 35312063940

 Nazionalità Coordinatore Ireland [IE]
 Sito del progetto http://www.angiopredict.com/
 Totale costo 7˙993˙254 €
 EC contributo 5˙999˙155 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2011-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-02-01   -   2016-01-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    ROYAL COLLEGE OF SURGEONS IN IRELAND

 Organization address address: Saint Stephen's Green 123
city: DUBLIN
postcode: 2

contact info
Titolo: Dr.
Nome: Annette
Cognome: Byrne
Email: send email
Telefono: 35314028673
Fax: 35312063940

IE (DUBLIN) coordinator 1˙199˙280.00
2    EPIGENOMICS AG

 Organization address address: KLEINE PRAESIDENTENSTR 1
city: BERLIN
postcode: 10178

contact info
Titolo: Ms.
Nome: Annett
Cognome: Freitag
Email: send email
Telefono: 4930243450
Fax: +49 30 24345555

DE (BERLIN) participant 794˙625.00
3    OncoMark Limited

 Organization address address: Weston Park 76
city: DUBLIN 14
postcode: -

contact info
Titolo: Dr.
Nome: Mairin
Cognome: Rafferty
Email: send email
Telefono: 35317163666
Fax: +353 1 716 3709

IE (DUBLIN 14) participant 697˙800.00
4    VIB

 Organization address address: Rijvisschestraat 120
city: ZWIJNAARDE - GENT
postcode: 9052

contact info
Titolo: Mr.
Nome: Rik
Cognome: Audenaert
Email: send email
Telefono: +32 9 244 66 11
Fax: +32 9 244 66 10

BE (ZWIJNAARDE - GENT) participant 677˙500.00
5    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

 Organization address address: BELFIELD
city: DUBLIN
postcode: 4

contact info
Titolo: Mr.
Nome: Donal
Cognome: Doolan
Email: send email
Telefono: +353 1 7161656
Fax: +353 1 7161216

IE (DUBLIN) participant 634˙800.00
6    SOMANTIX BV

 Organization address address: PROFESSOR BRONKHORSTLANN 10-92
city: BILTHOVEN
postcode: 3723 MB

contact info
Titolo: Dr.
Nome: Laurens
Cognome: Van Der Flier
Email: send email
Telefono: +3130 302296093

NL (BILTHOVEN) participant 587˙800.00
7    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

 Organization address address: SEMINARSTRASSE 2
city: HEIDELBERG
postcode: 69117

contact info
Titolo: Prof.
Nome: Matthias
Cognome: Ebert
Email: send email
Telefono: +49 6213833284
Fax: +49 6213833805

DE (HEIDELBERG) participant 541˙950.75
8    STICHTING VU-VUMC

 Organization address address: DE BOELELAAN 1105
city: AMSTERDAM
postcode: 1081 HV

contact info
Titolo: Dr.
Nome: Bauke
Cognome: Ylstra
Email: send email
Telefono: 31204442495

NL (AMSTERDAM) participant 436˙200.00
9    IRISH CLINICAL ONCOLOGY RESEARCH GROUP LIMITED LBG

 Organization address address: FITZWILLIAM SQUARE NORTH 60
city: DUBLIN
postcode: 2

contact info
Titolo: Dr.
Nome: Verena
Cognome: Murphy
Email: send email
Telefono: +353 1 6677211
Fax: +353 1 6697869

IE (DUBLIN) participant 277˙200.00
10    PINTAIL LTD

 Organization address address: SPRINGHILL AVENUE 77
city: BLACKROCK

contact info
Nome: Ciaran
Cognome: Clissmann
Email: send email
Telefono: +353 12899529

IE (BLACKROCK) participant 152˙000.00
11    VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG

 Organization address address: De Boelelaan 1105
city: AMSTERDAM
postcode: 1081 HV

contact info
Titolo: Dr.
Nome: B
Cognome: Ylstra
Email: send email
Telefono: 31204442495

NL (AMSTERDAM) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

metastatic    treatment    colorectal    diagnostic    cancer    clinical    trial    therapy    disease    bvz    paradigm    patients    benefit    validation    drug    predictive    angiopredict    sme    mcrc    discovery    combination    biomarkers   

 Obiettivo del progetto (Objective)

In recent years the treatment paradigm for metastatic colorectal cancer (mCRC) has evolved in complexity to include newly developed targeted therapeutics. In 2004 bevacizumab (bvz) [Avastin] became the first anti-angiogenic drug to be licensed in malignant disease, based on the results of a randomised trial in advanced metastatic colorectal cancer. Nevertheless, over the past six year period emerging data now indicates that bvz fails to produce an enduring clinical response in a high proportion of patients. Delivery of the drug as part of a combination treatment regimen in mCRC elicits transitory improvements in the form of tumour stasis or shrinkage. Inevitably however, the tumours begin to re-grow and the disease progresses. It is now universally agreed that the future use of bvz in mCRC (and other cancers) is likely to be greatly influenced by the availability of predictive biomarkers to allow selection of patients who will attain the greatest benefit. The ANGIOPREDICT paradigm relies on a modular platform for the integrated discovery and validation of predictive pharmacogenomic biomarkers for combination bvz therapy in mCRC. Through initiation of a multi-centre clinical trial, early discovery findings will be validated for markers of Intrinsic Resistance to therapy. Parallel optimization of companion in vitro diagnostic tests (IVDs) through exploitation of proven SME development and validation strategies will ensure a cross-sectoral benefit to the cancer patient, prescribing physician and more broadly, across European and global public health networks. Crucially, leading SME partners will expand business portfolios into a well-defined market, progress novel intellectual property and access several in-licensing opportunities. ANGIOPREDICT uniquely unites world-class molecular diagnostic biomarker discovery SMEs with leading clinical and academic entities to identify a new generation of individualized methods for predicting response to combination bvz therapy.

Altri progetti dello stesso programma (FP7-HEALTH)

HEPACUTE (2010)

Host and viral factors in acute hepatitis C

Read More  

AFFINITYPROTEOME (2009)

Advanced affinity tools and technologies for high throughput studies of the human proteome

Read More  

SYSTEMS MICROSCOPY (2011)

Systems microscopy – a key enabling methodology for next-generation systems biology

Read More